Combining metformin and Wegovy may offer additive benefits for patients with type 2 diabetes and obesity, addressing multiple aspects of metabolic health simultaneously
Patients stable on non-stimulants may transition to semaglutide with straightforward monitoring
Research use statement AlphaGen does not provide dosing advice, administration guidance, treatment recommendations, or therapeutic instructions
The CD4+/CD8+ ratio serves as a key marker of immune system aging, with a shift toward CD8+ dominance often linked to chronic inflammation, reduced pathogen defense, and heightened all-cause mortality risk
Now, these FDA-approved treatments, including popular options like semaglutide and tirzepatide, are widely recognized for their significant benefits in medical weight loss
Director, The Health Management Academy Key Takeaways GLP-1 drugs like Ozempic, Wegovy, Zepbound, and Mounjaro are now available across a wide cash-pay range, from roughly $150 to $450 per month, depending on drug, dose, and format
